Literature DB >> 32268361

Detection of ctDNA from Dried Blood Spots after DNA Size Selection.

Katrin Heider1,2, Jonathan C M Wan1,2, James Hall1,2, Jelena Belic1,2, Samantha Boyle1,2, Irena Hudecova1,2, Davina Gale1,2, Wendy N Cooper1,2, Pippa G Corrie2,3, James D Brenton1,2, Christopher G Smith1,2, Nitzan Rosenfeld1,2.   

Abstract

BACKGROUND: Recent advances in the study and clinical applications of circulating tumor DNA (ctDNA) are limited by practical considerations of sample collection. Whole-genome sequencing (WGS) is increasingly used for analysis of ctDNA, identifying copy-number alterations and fragmentation patterns. We hypothesized that low-depth/shallow WGS (sWGS) data may be generated from minute amounts of cell-free DNA, and that fragment-size selection may remove contaminating genomic DNA from small blood volumes. Dried blood spots have practical advantages for sample collection, may facilitate serial sampling, and could support novel study designs in humans and animal models.
METHODS: We developed a protocol for the isolation and analysis of cell-free DNA from dried blood spots using filter paper cards and bead-based size selection. DNA extracted and size-selected from dried spots was analyzed using sWGS and polymerase chain reaction (PCR).
RESULTS: Analyzing a 50 μL dried blood spot from frozen whole blood of a patient with melanoma, we identified ctDNA based on the presence of tumor-specific somatic copy-number alterations, and found a fragment-size profile similar to that observed in plasma DNA. We found alterations in different chromosomes in blood spots from 2 patients with high-grade serous ovarian carcinoma. Extending this approach to serial dried blood spots from mouse xenograft models, we detect tumor-derived cell-free DNA and identified ctDNA from the originally grafted ascites.
CONCLUSION: Our data suggest that ctDNA can be detected and monitored in dried blood spots from archived and fresh blood samples, enabling new approaches for sample collection and novel study/trial designs for both patients and in vivo models. © American Association for Clinical Chemistry 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32268361     DOI: 10.1093/clinchem/hvaa050

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa.

Authors:  Samuel Terkper Ahuno; Anna-Lisa Doebley; Thomas U Ahearn; Joel Yarney; Nicholas Titiloye; Nancy Hamel; Ernest Adjei; Joe-Nat Clegg-Lamptey; Lawrence Edusei; Baffour Awuah; Xiaoyu Song; Verna Vanderpuye; Mustapha Abubakar; Maire Duggan; Daniel G Stover; Kofi Nyarko; John M S Bartlett; Francis Aitpillah; Daniel Ansong; Kevin L Gardner; Felix Andy Boateng; Anne M Bowcock; Carlos Caldas; William D Foulkes; Seth Wiafe; Beatrice Wiafe-Addai; Montserrat Garcia-Closas; Alexander Kwarteng; Gavin Ha; Jonine D Figueroa; Paz Polak
Journal:  NPJ Precis Oncol       Date:  2021-09-17

Review 2.  Next-Generation Liquid Biopsies: Embracing Data Science in Oncology.

Authors:  Y R Im; D W Y Tsui; L A Diaz; J C M Wan
Journal:  Trends Cancer       Date:  2020-12-13

3.  Rethinking cancer clinical trials for COVID-19 and beyond.

Authors:  Mehmet Goksu; Bruno H R de Paula; Gary J Doherty
Journal:  Nat Cancer       Date:  2020-05-29

4.  Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.

Authors:  Carolin M Sauer; Katrin Heider; Nitzan Rosenfeld; James D Brenton; Jelena Belic; Samantha E Boyle; James A Hall; Dominique-Laurent Couturier; Angela An; Aadhitthya Vijayaraghavan; Marika Av Reinius; Karen Hosking; Maria Vias
Journal:  EMBO Mol Med       Date:  2022-06-13       Impact factor: 14.260

Review 5.  Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures.

Authors:  Angela Oberhofer; Abel J Bronkhorst; Carsten Uhlig; Vida Ungerer; Stefan Holdenrieder
Journal:  Diagnostics (Basel)       Date:  2022-07-29

Review 6.  Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.

Authors:  Marissa F Dockendorf; Bryan J Hansen; Kevin P Bateman; Matthew Moyer; Jyoti K Shah; Lisa A Shipley
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

7.  Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.

Authors:  Tun Kiat Ko; Elizabeth Lee; Cedric Chuan-Young Ng; Valerie Shiwen Yang; Mohamad Farid; Bin Tean Teh; Jason Yongsheng Chan; Nagavalli Somasundaram
Journal:  Front Oncol       Date:  2022-02-22       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.